<DOC>
	<DOCNO>NCT02658929</DOCNO>
	<brief_summary>Study CRB-401 2-part , non-randomized , open label , multi-site Phase 1 study bb2121 adult relapsed/refractory multiple myeloma ( MM ) .</brief_summary>
	<brief_title>Study bb2121 Multiple Myeloma</brief_title>
	<detailed_description>Part A study enroll adult multiple myeloma use 3+3 dose escalation approach . An expansion cohort enrol follow dose selection . Following consent , enrolled subject undergo leukapheresis procedure collect autologous mononuclear cell manufacture investigational drug product ( bb2121 ) . Following manufacture drug product , subject receive lymphodepletion prior bb2121 infusion . All subject follow 24 month Study CRB-401 . All subject complete study , well withdraw study receive bb2121 reason death meeting early termination criterion , ask continue undergo long-term follow-up companion study LTF-305 15 year last bb2121 infusion , focus long-term safety efficacy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>â‰¥ 18 year age time sign informed consent Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Diagnosis MM relapse refractory disease least 3 different prior line therapy include proteasome inhibitor ( e.g. , bortezomib carfilzomib ) immunomodulatory therapy ( IMiD ; e.g. , lenalidomide pomalidomide ) , `` double refractory '' disease proteasome inhibitor IMiD , define progression within 60 day treatment agent . Subjects must measurable disease Women childbearing potential ( WCBP ) must negative serum pregnancy test prior treatment . All sexually active WCBP sexually active male subject must agree use effective method birth control throughout study Subjects know central nervous system disease Inadequate hepatic function Inadequate renal function Inadequate bone marrow function Presence active infection within 72 hour Subjects history stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control Significant comorbid condition disease judgment Investigator would place subject undue risk interfere study ; example include , limited , cirrhotic liver disease , sepsis , recent significant traumatic injury , condition Known human immunodeficiency virus ( HIV ) positivity Subjects history stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>